Open the Nature Biotechnology Advertorial Improving Pre-Clinical Immunogenicity Assessment with MHC Class II Associated Peptide Proteomics (MAPPs)

Read Abzena’s advertorial in nature biotechnology on how utilising highly powerful mass spectrometry in combination with ex-vivo T cell assays has significantly improved our ability to identify MHC Class II binding peptides and T cell epitopes. This gives far more precision to re-engineer proteins to reduce their immunogenicity.

Interested in our services? Get In Touch